We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Nanobiotix | EU:NANO | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.06 | -0.91% | 6.51 | 6.45 | 6.525 | 6.55 | 6.33 | 6.55 | 35,093 | 02:01:00 |
By Colin Kellaher
U.S.-listed shares of Nanobiotix surged in premarket trading Monday after the clinical-stage biotechnology company said it inked a licensing, co-development and commercialization agreement potentially worth billions of dollars with a unit of drug giant Johnson & Johnson.
Paris-based Nanobiotix said it will grant J&J's Janssen Pharmaceutical unit a worldwide license for the development and commercialization of NBTXR3, a radioenhancer currently being evaluated in several studies across solid tumor indications.
Nanobiotix said it will receive near-term cash and operational support valued up to $60 million, including a $30 million upfront cash licensing fee and up to $30 million in in-kind regulatory and development support for a current Phase 3 study evaluating NBTXR3 for the treatment of patients with locally advanced head and neck cancer.
Nanobiotix said it is eligible for up to $1.8 billion in payments related to potential development, regulatory and sales milestones, along with royalties on product sales.
The company said the agreement also includes a framework for up to $650 million in additional milestone payments for five new indications that Janssen may develop at its discretion, as well as up to $220 million per indication that Nanobiotix may develop in alignment with Janssen.
Nanobiotix's U.S.-listed shares, which closed Friday at $5.18, were recently up nearly 52% to $7.85 in premarket trading. The company's Paris-listed shares were up 53% to EUR7.15.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 10, 2023 06:42 ET (10:42 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Nanobiotix Chart |
1 Month Nanobiotix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions